Who are Salmeterol/fluticasone Diskus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Extra fine Formoterol/Beclomethasone, Salmeterol/ fluticasone propionate, Seretide 500 Accuhaler, Salmeterol/Fluticasone Capsair®, FF/VI 100/25 Inhalation Powder NDPI, Seretide® Accuhaler® 250/50 µg/actuation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/salmeterol-fluticasone-diskus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Salmeterol/fluticasone Diskus — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Salmeterol/fluticasone Diskus (Salmeterol/fluticasone Diskus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist/inhaled corticosteroid combination. Area: Respiratory/Pulmonology.

marketed Long-acting beta-2 agonist/inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol/fluticasone Diskus (Salmeterol/fluticasone Diskus) — AstraZeneca. Salmeterol/fluticasone combines a long-acting beta-2 agonist that dilates airways with an inhaled corticosteroid that reduces airway inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Salmeterol/fluticasone Diskus TARGET	Salmeterol/fluticasone Diskus	AstraZeneca	marketed	Long-acting beta-2 agonist/inhaled corticosteroid combination	Beta-2 adrenergic receptor; glucocorticoid receptor
Extra fine Formoterol/Beclomethasone	Extra fine Formoterol/Beclomethasone	National Institute of Respiratory Diseases, Mexico	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA)	Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate	Salmeterol/ fluticasone propionate	GlaxoSmithKline	marketed	Long-acting beta-2 agonist / inhaled corticosteroid combination	Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide 500 Accuhaler	Seretide 500 Accuhaler	University of Southampton	marketed	Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/Fluticasone Capsair®	Salmeterol/Fluticasone Capsair®	Neutec Ar-Ge San ve Tic A.Ş	marketed	Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; glucocorticoid receptor
FF/VI 100/25 Inhalation Powder NDPI	FF/VI 100/25 Inhalation Powder NDPI	GlaxoSmithKline	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist combination	Beta-2 adrenergic receptor; glucocorticoid receptor
Seretide® Accuhaler® 250/50 µg/actuation	Seretide® Accuhaler® 250/50 µg/actuation	Chiesi Farmaceutici S.p.A.	phase 3	Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS)	Beta-2 adrenergic receptor; Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist/inhaled corticosteroid combination class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol/fluticasone Diskus — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-fluticasone-diskus. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing